Dehghanbanadaki Hojat, Aazami Hossein, Razi Farideh, Nasli-Esfahani Ensieh, Norouzi Parviz, Hashemi Ehsan
Metabolomics and Genomics Research Center, Endocrinology and Metabolism Molecular- Cellular Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
Metabolic Disorders Research Center, Endocrinology and Metabolism Molecular - Cellular Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
Diabetes Metab Syndr. 2022 Apr;16(4):102450. doi: 10.1016/j.dsx.2022.102450. Epub 2022 Mar 15.
BACKGROUND AND AIMS: Exosome as a novel biomarker reflecting cell behavior in normal and pathological conditions such as diabetes is being the center of academic attention. Therefore, we aimed to study the research output of exosome in diabetes globally. METHODS: We conducted a bibliometric approach to analyze publications on exosome and diabetes from the beginning to 2021 based on keyword search in the Scopus. Annual publications, citations, contributions, co-authorships, and co-occurrences were analyzed and plotted using VOSviewer and GraphPad Prism. RESULTS: 410 original articles and 149 reviews have published between 2009 and 2021. China and the USA were top countries in research output, sponsorship, and international collaborations. The top journals were Scientific Reports, Stem Cell Research and Therapy and Diabetes. The top institution was the University of Queensland in Australia. The top author was Chopp M. Co-occurrence analysis indicated that researchers focused on 1) extracellular vesicles in insulin resistance induced by metabolic disorders like obesity and diabetes mellitus; 2) diagnostic applicability of exosomal microRNAs as biomarkers for diabetic nephropathy; 3) therapeutic effect of exosome in wound healing and endothelial dysfunction during diabetes mellitus; and 4) The oxidative stress, autophagy, apoptosis, fibrosis, inflammation and angiogenesis mediated by exosomes during diabetes. CONCLUSION: The trend in research output has been increased in this field, and advanced countries are involved much more than other countries in terms of research, financial support, and international collaboration. The bibliometric results could be beneficial for further studies in better understanding of novel ideas in exosome and diabetes fields.
背景与目的:外泌体作为一种反映正常和病理状态(如糖尿病)下细胞行为的新型生物标志物,正成为学术关注的焦点。因此,我们旨在研究全球范围内外泌体在糖尿病领域的研究成果。 方法:我们采用文献计量学方法,基于在Scopus中进行的关键词搜索,分析了从开始到2021年关于外泌体和糖尿病的出版物。使用VOSviewer和GraphPad Prism分析并绘制了年度出版物、引用量、贡献、共同作者情况和共现情况。 结果:2009年至2021年间共发表了410篇原创文章和149篇综述。中国和美国是研究产出、资助和国际合作方面的领先国家。顶级期刊为《科学报告》《干细胞研究与治疗》和《糖尿病》。顶级机构是澳大利亚的昆士兰大学。顶级作者是Chopp M。共现分析表明,研究人员关注以下方面:1)肥胖和糖尿病等代谢紊乱诱导的胰岛素抵抗中的细胞外囊泡;2)外泌体微小RNA作为糖尿病肾病生物标志物的诊断适用性;3)外泌体在糖尿病伤口愈合和内皮功能障碍中的治疗作用;4)糖尿病期间外泌体介导的氧化应激、自噬、凋亡、纤维化、炎症和血管生成。 结论:该领域的研究产出呈上升趋势,在研究、资金支持和国际合作方面,发达国家比其他国家参与度更高。文献计量学结果有助于进一步研究,以更好地理解外泌体和糖尿病领域的新观点。
Diabetes Metab Syndr. 2022-4
Front Pharmacol. 2023-3-9
Int J Nanomedicine. 2020-6-26
Front Cardiovasc Med. 2022-12-20
Diabetes Metab Syndr. 2021
J Cancer Res Clin Oncol. 2024-8-30
Medicine (Baltimore). 2023-9-29
Front Endocrinol (Lausanne). 2023
Front Endocrinol (Lausanne). 2023-2-6